Weight change, genetics and antiepileptic drugs

@article{Chukwu2014WeightCG,
  title={Weight change, genetics and antiepileptic drugs},
  author={Joseph Chukwu and Norman Delanty and David Webb and Gianpiero L. Cavalleri},
  journal={Expert Review of Clinical Pharmacology},
  year={2014},
  volume={7},
  pages={43 - 51}
}
Weight gain caused by antiepileptic drugs (AEDs) constitutes a serious problem in the management of people with epilepsy. AEDs associated with weight gain include sodium valproate, pregabalin and vigabatrin. Excessive weight gain can lead to non-compliance with treatment and to an exacerbation of obesity-related conditions. The mechanisms by which AEDs cause weight gain are not fully understood. It is likely that weight change induced by some AEDs has a genetic underpinning, and recent… 
Pharmacogenomics of Medication‐Induced Weight Gain and Antiobesity Medications
TLDR
There are more robust studies of medication associated with weight gain and pharmacogenetics, and more studies are needed to understand the role of pharmacogenomics in antiobesity medications.
[Pharmacogenetic markers of metabolic disorders in the treatment with valproic acid].
The review includes studies on the association between the use of VA drugs and weight gain in patients with epilepsy as well as other valproate-induced adverse drug reactions, including insulin
Efficacy and tolerability of antiseizure drugs
  • T. Hakami
  • Medicine
    Therapeutic advances in neurological disorders
  • 2021
TLDR
A complete overview of the current state of the literature about the efficacy and tolerability of ASDs is presented and guidance to clinicians about selecting appropriate ASDs for initial treatment of epilepsy according to different seizure types and epilepsy syndromes is provided based on the current literature and recent US and UK practical guidelines.
Modern pharmacological treatment of obese patients
TLDR
In this article, the data available on different aspects of drug treatment in the obese patient is summarized with the hope of improving patient care.
Effects of Paullinia cupana extract on lamotrigine pharmacokinetics in rats: A herb-drug interaction on the gastrointestinal tract with potential clinical impact.
TLDR
Overall, the results revealed a pharmacokinetic-based herb-drug interaction between P. cupana extract and LTG, mainly after their co-administration.
Short-term effects of Garcinia cambogia extract on the pharmacokinetics of lamotrigine given as a single-dose in Wistar rats.
Garcinia cambogia supplements are widely used for weight loss. Knowing that epilepsy patients are at greater risk of developing overweight/obesity, the investigation of herb-drug interactions
Ketogenic diet in epileptic children: impact on lipoproteins and oxidative stress
TLDR
Clinicians and researchers are invited to investigate the lipid and oxidative metabolism in their clinical practice and trials, respectively, to update the knowledge about the adverse effects of KD on lipoproteins, lipid profile, and cardiometabolic risk.
Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice
TLDR
This paper reviews the main pharmacological treatments for BED and provides an expert opinion based on the available evidence and on the authors’ clinical experience with patients affected by BED.
Neuropharmacology of Antiseizure Drugs
  • T. Hakami
  • Medicine
    Neuropsychopharmacology reports
  • 2021
TLDR
This article aims to educate non-neurologists and medical students about the new frontiers in the pharmacology of ASDs and presents the current state of the literature on the efficacy and tolerability of these agents.
Pharmacogenetic Markers for Metabolic Impairments in Treatment with Valproic Acid
This review presents studies of the association between the use of sodium valproate formulations and increases in body weight in patients with epilepsy, as well as other valproate-induced side
...
1
2
3
...

References

SHOWING 1-10 OF 123 REFERENCES
Effect of Antiepileptic Drugs on Bodyweight
TLDR
The data demonstrate that AEDs can differ substantially in their effects on weight; some,such as valproate and carbamazepine, increase weight; others, such as topiramate and felbamate, decrease it; still others,Such as lamotrigine, levetiracetam and phenytoin, are weight neutral.
Metabolic concerns associated with antiepileptic medications
TLDR
Doctors should be aware of the metabolic changes that can be associated with AED use and the potential effects of these changes during long-term therapy, because many of them are subtle and may take years to become clinically apparent.
Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide.
TLDR
This chapter provides a review of potential mechanisms of actions of the two AEDs causing strong weight loss: topiramate and zonisamide based on in vivo studies in animal models for obesity and of clinical studies exploring these two drugs as single entities or in combinations with other agents.
Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients
TLDR
It is shown that low serum leptin level is associated with weight loss in overweight female epilepsy patients, which may be beneficial for selecting AEDs and provide clues for the pathophysiology of zonisamide-induced weight loss.
[Changes of body weight and galanin in epileptic children treated with topiramate].
TLDR
Topiramate treatment may lower the body weight and reduce appetite in part of children with epilepsy which may be mediated by the reduced plasma galanin level.
Weight issues for people with epilepsy—A review
TLDR
It is critical to weigh patients regularly and AED selection should be based on each patient's profile without sacrificing therapeutic efficacy, as a sedentary lifestyle can contribute to weight gain.
Bodyweight Gain and Anticonvulsants
TLDR
How to better define the risk factors for the development of anticonvulsant-induced bodyweight gain and uncover the mechanisms behind it is illustrated.
Valproic Acid related metabolic syndrome in patients with epilepsy.
TLDR
According to the preliminary data VPA monotherapy increases the risk of metabolic syndrome in patients with epilepsy, but BMI did not differ between VPAmonotherapy study group, CBZ monotherapyStudy group and controls.
...
1
2
3
4
5
...